|
| Press Releases |
|
 |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
QS Energy Receives Initial Order for Multi-Year AOT Technology Deployment
Jun 21, 2025 22:01 HKT/SGT
|
|
|
Ditchit Detonates Iconic Twitter Bird to Symbolize Launch of Local Marketplace
Jun 21, 2025 06:00 HKT/SGT
|
|
|
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025 
Jun 20, 2025 23:00 HKT/SGT
|
|
|
Global Economic Shifts in Focus as Madrid Professor Addresses SPIEF 2025 Opening Session
Jun 20, 2025 23:00 HKT/SGT
|
|
|
BW Digital and BW ESS launch BW Velora to drive greater digital sustainability
Jun 20, 2025 19:40 HKT/SGT
|
|
|
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health
Jun 20, 2025 19:06 JST
|
|
|
New method to blend functions for soft electronics
Jun 20, 2025 15:00 HKT/SGT
|
|
|
Legacy and Lifestyle: U.S. Polo Assn. Hosts Iconic Party at Pitti Uomo 108 in Florence, Italy
Jun 19, 2025 22:30 HKT/SGT
|
|
|
Sharp Launches A2 Size ePoster Color Electronic Paper Display
Jun 19, 2025 12:08 JST
|
|
|
CleverTap Launches 'Promos' - The Industry-First All-In-One Rewards Management Platform
Jun 19, 2025 10:19 HKT/SGT
|
|
|
Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations
Jun 19, 2025 10:25 JST
|
|
|
Canstar Strengthens Technical Advisory Board with the Appointment of Geologist and VMS Mineralization Expert, Dr. Stephen J. Piercey, P.Geo., FGC
Jun 19, 2025 09:15 HKT/SGT
|
|
|
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 9:30 JST
|
|
|
Euro Manganese and Integrals Power Sign LOI and Offtake Term Sheet to Strengthen LMFP Battery Supply Chain
Jun 19, 2025 06:59 HKT/SGT
|
|
|
Data Turing Launches to Automate Brand Reputation Using Verifiable Truth
Jun 18, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
